SCHOTT Pharma AG & Co. KGaA
Frankfurt Stock Exchange 1SXP.F
SCHOTT Pharma AG & Co. KGaA Price to Book Ratio (P/B) on January 14, 2025: 4.42
-
SCHOTT Pharma AG & Co. KGaA 52-week high Price to Book Ratio (P/B) is 9.75 on March 20, 2024, which is 120.62% above the current Price to Book Ratio (P/B).
-
SCHOTT Pharma AG & Co. KGaA 52-week low Price to Book Ratio (P/B) is 4.23 on December 17, 2024, which is -4.25% below the current Price to Book Ratio (P/B).
-
SCHOTT Pharma AG & Co. KGaA average Price to Book Ratio (P/B) for the last 52 weeks is 7.51.
| Date | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield | Price to Earnings Ratio (P/E) |
|---|
| CEO | Mr. Andreas Reisse |
| IPO Date | Sept. 26, 2023 |
| Location | Germany |
| Headquarters | Hattenbergstrasse 10 |
| Employees | 4,681 |
| Sector | Health Care |
| Industries | |
SCHOTT Pharma AG & Co. KGaA develops, produces, and sells drug containment solutions and delivery systems for injectable drugs to the pharmaceutical and biotechnology industries worldwide. The company offers polymer and glass syringes, ampoules, vials, and cartridges. Its syringe products include syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; and SCHOTT TOPPAC unique, a polymer container. The company's cartridge products comprise cartriQ, a pharmaceutical glass cartridge for peptide and protein-based injectables; cartriQ Large Volume, a pharmaceutical glass cartridge for large-volume injectables; Cartridges Double Chamber, a pharmaceutical glass cartridge for lyophilized drugs; Cartridges Break Resistant, a pharmaceutical glass cartridge; and TopLine and StandardLine cartridges. Its vial products include adaptiQ, a pharmaceutical glass vial for injectables; EVERIC pure, a pharmaceutical glass vial for unmatched drug stability; EVERIC care, a pharmaceutical glass vial for a pH range; EVERIC strong & smooth, a pharmaceutical glass vial for the filling line performance; SCHOTT Type I plus, a pharmaceutical glass vial for drug formulations; SCHOTT TopLyo, a pharmaceutical glass vial to avoid fogging for lyophilized drugs; and TopLine and StandardLine vials. Its ampoule products comprise Ampoules easyOPC, a pharmaceutical glass ampoule for ampoule opening; Ampoules Anti-Counterfeiting, a pharmaceutical glass ampoule for protection against drug counterfeiting; and StandardLine ampoules. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email